A National Institute of Health Research funded study is looking at whether a tablet usually used in patients with heart problems could also be effective in central serous retinopathy (CSR). Early studies suggest the tablet can cause CSR to resolve.
The study is looking for volunteers who have had symptoms such as blurred vision for at least four months and who are under 60 years of age. Volunteers must never have been treated, with injections or laser treatment, for CSR in their affected eye. Volunteers will be followed for a year and will receive either the tablet (eplerenone) or a placebo. They can also receive the usual standard of care for their hospital as well as the drug treatment.
The study is being led by Professor Andrew Lotery in Southampton with colleagues participating in 22 hospitals around the UK. Currently over 30 patients are participating in the study with a target of 104 patients being enrolled. Further information about the study is available by going to the website cteu.bris.ac.uk/our-studies and then going to the Ophthalmology section and the VICI tab. If you are interested in finding out more you can contact the study team via the study email address which is email@example.com